AVITA Medical Reports Mixed Q4 2025 Results Amid Reimbursement Challenges
Event summary
- Q4 2025 revenue declined 4% YoY to $17.6M due to reimbursement headwinds.
- Full-year 2025 revenue grew 11% to $71.6M, meeting revised guidance.
- Net loss narrowed to $48.6M in 2025 from $61.8M in 2024.
- Secured $60M credit facility with Perceptive Advisors in January 2026.
- Six of seven Medicare Administrative Contractors published RECELL payment rates by January 2026.
The big picture
AVITA Medical's 2025 performance reflects the ongoing challenges of reimbursement disruption in the acute wound care market. The company's strategic focus on cost reduction and debt refinancing positions it for potential growth as reimbursement headwinds ease. The integration of its product portfolio into staged wound care pathways could drive deeper utilization in core burn and trauma centers.
What we're watching
- Reimbursement Normalization
- Whether the resolution of Medicare payment rate issues will drive sustained RECELL utilization growth in 2026.
- Clinical Trial Progress
- The pace at which Cohealyx I and PermeaDerm I studies deliver data and potential regulatory approvals.
- Operational Efficiency
- How AVITA Medical maintains its improved cash efficiency while investing in commercial expansion.